Yes, removing the prostate can get rid of prostate cancer, but only when every cancer cell is confined to the gland and the surgeon removes it entirely. Surgery cures roughly 75-85% of men whose cancer is organ-confined at operation, and cure rates fall sharply once tumor has escaped the capsule. The operation removes the whole prostate, not the cancer alone, so what happens to residual disease depends on where cells sit at the moment of surgery.

What radical prostatectomy actually removes

The operation is called radical prostatectomy because it removes the entire prostate gland plus the seminal vesicles, the paired sacs behind the bladder that store semen. Those vesicles sit directly against the prostate, and tumor can slide into them before it ever reaches a lymph node. Leaving them behind would leave a known escape route. The surgeon also takes a margin of surrounding tissue, and the vas deferens is divided where it meets the gland.

Nerve bundles run along the prostate's outer surface and control erections. Whether they are spared depends on where the tumor sits and how aggressive it looks, not on convenience. A positive surgical margin means cancer cells touch the inked edge of the removed specimen. That does not automatically mean cancer remains in the body, but it raises the risk that some do.

Lymph nodes in the pelvis are sampled during the same operation when risk warrants it. They are the first drainage station for prostate fluid, so a positive node means cells have already left the gland's neighborhood. This is why the operation is a staging procedure as much as a treatment. The pathology report on the removed tissue, not the biopsy, delivers the final verdict on what was actually there.

Why location decides whether surgery can cure

Prostate cancer kills by escaping the capsule and traveling, so cure requires that no cell has done so at the moment of surgery. The gland has no true capsule in the anatomical sense, only a thin fibrous layer that tumor can breach. Once cells cross it, they enter periprostatic fat and from there reach nerves, vessels, and lymphatics that lead outward. Microscopic escape can happen while the tumor still looks small on imaging.

This is why Gleason grade and stage matter more than tumor size. A Gleason 6 tumor is built of cells that look nearly normal and grows slowly, and it almost never behaves like a killer. Gleason 8-10 tumors are poorly differentiated, meaning the cells have lost the architecture that keeps them in place, and they can seed distant sites early. Grade tells you how likely cells are to travel, and stage tells you whether they already have.

Surgery removes what the surgeon can see and feel plus a margin. It cannot remove cells that settled in bone marrow or distant nodes before the operation. That is the central limitation, and it explains why the same operation cures one man and fails another with a similar-looking tumor. The difference is usually microscopic spread that no scan or frozen section can detect.

How often surgery cures, in numbers

Among men whose cancer is confined to the prostate at pathology, roughly three in four to five in six remain free of biochemical recurrence a decade after surgery. Biochemical recurrence means a rising PSA after the operation, the earliest signal that some cancer tissue remains. PSA should fall to undetectable within about six weeks of a successful radical prostatectomy, because the prostate is the main source of the protein. A detectable or rising PSA after that point is the first warning.

If tumor has reached the seminal vesicles or the lymph nodes, the cure rate drops substantially, often to well under half. Positive margins alone are a softer signal: many men with a positive margin never recur, and many who do recur are still salvageable with radiation. That distinction between margin status and node status is one of the most misunderstood points in prostate cancer care. One is a local worry, the other is a systemic one.

For men with low-risk disease, surgery and radiation produce similar long-term cancer control, and active surveillance is a legitimate third path. Roughly 30-40% of newly diagnosed men fall into a low-risk category where watching is reasonable, though the exact proportion depends on how aggressively the population is screened. Screening intensity changes the denominator, which is why quoted percentages vary between health systems.

Surgery versus the alternatives

Approach What it removes or does Best suited to Main trade-off
Radical prostatectomy Whole gland, seminal vesicles, often nodes Organ-confined disease, age under about 70, life expectancy over 10 years Incontinence and erectile dysfunction risk; requires anesthesia
External beam radiation Kills cells in place over weeks Localized disease, older men, those unfit for surgery Bladder and bowel irritation; slow PSA decline over months
Brachytherapy Seeds radiation placed inside the gland Low-risk, small glands Urinary symptoms; less data in high-risk disease
Active surveillance Monitors with PSA and repeat biopsies Low-risk, Gleason 6 disease Anxiety and repeat biopsy burden; risk of missed progression
Hormone therapy alone Lowers testosterone to starve cells Advanced or metastatic disease Not curative; side effects from testosterone suppression

The table's core lesson is that only surgery and radiation are delivered with curative intent in localized disease. Hormone therapy shrinks and slows tumor but does not eliminate it, so it is used alongside definitive treatment, not instead of it, when cure is the goal. Choosing between surgery and radiation often comes down to side-effect profile and patient preference rather than a clear survival winner.

Edge cases that change the answer

Age and life expectancy reshape the math. A man with serious heart disease and a 10-year life expectancy may never be harmed by a slow-growing prostate tumor, so the operation's risks can outweigh its benefit. Conversely, a healthy 55-year-old with Gleason 4+3 disease gains more from definitive treatment because he has decades in which residual cancer could surface.

Very high-risk disease is a different problem. When scans show tumor extending beyond the capsule or into nodes, surgery alone is rarely enough and is often combined with radiation or systemic therapy. In that setting the operation is one part of a multimodality plan, not a standalone cure. Removing the prostate still has a role in selected men, but the goal shifts toward control rather than guaranteed elimination.

A rising PSA after surgery is not always a death sentence. Salvage radiation to the prostate bed can still cure a meaningful share of men whose recurrence is local, especially when given early while PSA is low. That window closes as PSA climbs and as time passes. This is the strongest argument for regular PSA monitoring after the operation rather than treating surgery as a finish line.

Common misconceptions

The biggest myth is that surgery "gets it all" as long as the surgeon is skilled. Skill matters, but biology matters more, and microscopic spread cannot be seen or felt. A brilliant surgeon removing a tumor that has already seeded a lymph node has not failed; the disease had simply left before the operation began.

Another myth is that a positive margin means the operation failed. Many men with positive margins never recur, and many recurrences are still curable with salvage radiation. Margin status is a risk marker, not a verdict. Treating it as proof of residual cancer leads to unnecessary fear and sometimes unnecessary immediate treatment.

A third misconception conflates survival with cure. Surgery clearly extends life in men with higher-risk localized disease, but "cure" means no cancer ever returns, which is a stricter bar. Some men die of other causes with no evidence of recurrence, which is a good outcome even if it is not the same as proven cure. The distinction matters when weighing treatment intensity against quality of life.

The counterintuitive detail worth holding onto: removing the prostate can eliminate the cancer while a man still carries microscopic deposits elsewhere, so the operation succeeds locally and fails systemically at the same time. The pathology report reveals this after the fact. That is why the six-week PSA and subsequent monitoring are as important as the surgery itself.

Practical steps and thresholds

Get a confirmatory biopsy review before committing to surgery, because Gleason grading varies between pathologists and grade drives everything downstream. Ask for a risk category in plain terms: low, intermediate, or high, based on PSA, Gleason score, and clinical stage together. Expect PSA to be undetectable by about six weeks after surgery; confirm the timing with your surgeon rather than assuming a universal date. If PSA becomes detectable or rises, discuss salvage radiation early, while the value is still low, because the window narrows as it climbs. Do not treat a positive margin as automatic residual cancer; ask whether the margin was focal or extensive and where it sat. For low-risk Gleason 6 disease, ask whether active surveillance is a reasonable alternative before accepting surgery's side effects.

Where the limits of the evidence sit

No operation can promise cure, because cure is defined retrospectively by the absence of recurrence over years. Surgery's long-term outcomes come from large cohort series and trials, and those numbers describe groups, not individuals. Two men with identical pathology can have different outcomes, which is biology defying the averages.

Imaging cannot resolve microscopic disease. Even modern PSMA PET scans miss small deposits, so a negative scan before surgery does not guarantee organ confinement. This is a hard limit of technology, not a failure of the surgeon, and it is why pathology on the removed gland remains the gold standard for staging.

The most honest answer to the question is conditional: removing the prostate gets rid of cancer when the cancer is still inside the prostate. It is the right operation for the right tumor at the right time, and its success is measured by what the pathology report and the years of PSA follow-up reveal. Men should hear that conditional answer plainly rather than a promise of cure.